Supernus [SUPN] vs Haleon Plc - ADR [HLN] Detailed Stock Comparison

Supernus Pharmaceuticals Inc.

NASDAQ
Loading...

Haleon Plc - ADR

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Supernus Pharmaceuticals Inc. wins in 6 metrics, Haleon Plc - ADR wins in 14 metrics, with 0 ties. Haleon Plc - ADR appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Supernus Pharmaceuticals Inc. Haleon Plc - ADR Better
P/E Ratio (TTM) 40.66 18.72 Haleon Plc - ADR
Price-to-Book Ratio 2.66 1.88 Haleon Plc - ADR
Debt-to-Equity Ratio 3.86 52.37 Supernus Pharmaceuticals Inc.
PEG Ratio -0.33 15.42 Haleon Plc - ADR
EV/EBITDA 22.87 33.08 Supernus Pharmaceuticals Inc.
Profit Margin (TTM) -5.36% 15.11% Haleon Plc - ADR
Operating Margin (TTM) 5.57% 23.17% Haleon Plc - ADR
EBITDA Margin (TTM) 5.57% 23.17% Haleon Plc - ADR
Return on Equity -3.68% 10.27% Haleon Plc - ADR
Return on Assets (TTM) 1.14% 4.67% Haleon Plc - ADR
Free Cash Flow (TTM) $45.99M $2.22B Haleon Plc - ADR
Dividend Yield N/A 1.63% N/A
1-Year Return 45.68% -20.18% Supernus Pharmaceuticals Inc.
Price-to-Sales Ratio (TTM) 3.93 3.78 Haleon Plc - ADR
Enterprise Value $2.68B $122.54B Haleon Plc - ADR
EV/Revenue Ratio 3.73 8.23 Supernus Pharmaceuticals Inc.
Gross Profit Margin (TTM) 89.13% 55.38% Supernus Pharmaceuticals Inc.
Revenue per Share (TTM) $13 $2 Supernus Pharmaceuticals Inc.
Earnings per Share (Diluted) $-0.68 $0.50 Haleon Plc - ADR
Beta (Stock Volatility) 0.73 0.33 Haleon Plc - ADR
Short % of Float 11.09% 0.43% Haleon Plc - ADR

Supernus Pharmaceuticals Inc. vs Haleon Plc - ADR Stock Performance Analysis

Loading Price Chart...

SUPN
HLN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Supernus Pharmaceuticals Inc.-0.08%-7.75%-9.38%-20.00%-0.11%-10.92%
Haleon Plc - ADR0.23%-5.84%-5.84%-19.96%-10.03%-13.00%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Supernus Pharmaceuticals Inc.45.68%37.73%54.55%136.46%673.53%673.53%
Haleon Plc - ADR-20.18%9.16%22.27%22.27%22.27%22.27%

Performance & Financial Health Analysis: Supernus Pharmaceuticals Inc. vs Haleon Plc - ADR

MetricSUPNHLN
Market Information
Market Cap i$2.83B$42.40B
Market Cap CategoryMid capLarge cap
10 Day Avg. Volume i492,6946,594,249
90 Day Avg. Volume i568,6017,985,230
Last Close$44.03$8.72
52 Week Range$30.83 - $59.68$8.65 - $11.30
% from 52W High-26.21%-22.83%
All-Time High$61.25 (Jun 25, 2018)$11.42 (Jun 02, 2025)
% from All-Time High-28.11%-23.64%
Growth Metrics
Quarterly Revenue Growth0.22%0.01%
Quarterly Earnings Growth0.21%0.86%
Financial Health
Profit Margin (TTM) i-0.05%0.15%
Operating Margin (TTM) i0.06%0.23%
Return on Equity (TTM) i-0.04%0.10%
Debt to Equity (MRQ) i3.8652.37
Cash & Liquidity
Book Value per Share (MRQ)$18.48$4.99
Cash per Share (MRQ)$5.36$0.15
Operating Cash Flow (TTM) i$47.33M$3.56B
Levered Free Cash Flow (TTM) i$101.29M$1.89B
Dividends
Last 12-Month Dividend Yield iN/A1.63%
Last 12-Month Dividend iN/A$0.17

Valuation & Enterprise Metrics Analysis: Supernus Pharmaceuticals Inc. vs Haleon Plc - ADR

MetricSUPN (Apr 22, 2026)HLN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i40.6618.72
Forward P/E i11.6415.42
PEG Ratio i-0.3315.42
Price to Sales (TTM) i3.933.78
Price to Book (MRQ) i2.661.88
Market Capitalization
Market Capitalization i$2.83B$42.40B
Enterprise Value i$2.68B$122.54B
Enterprise Value Metrics
Enterprise to Revenue i3.738.23
Enterprise to EBITDA i22.8733.08
Risk & Other Metrics
Beta i0.730.33
Book Value per Share (MRQ) i$18.48$4.99

Financial Statements Comparison: Supernus Pharmaceuticals Inc. vs Haleon Plc - ADR

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricSUPN (2025)HLN (2025)
Revenue/Sales i718.95M11.03B
Cost of Goods Sold i74.56M3.95B
COGS % of Revenue i10.4%35.8%
Gross Profit i644.39M7.08B
Gross Margin i89.6%64.2%
Research & Development i106.24M316.00M
Operating Income (EBIT) i-36.86M2.41B
Operating Margin i-5.1%21.9%
EBITDA i67.95M2.81B
EBITDA Margin i9.5%25.5%
Pre-Tax Income i-49.03M2.15B
Pre-Tax Income % of Revenue i-6.8%19.5%
Income Tax i-10.48M472.00M
Income Tax % of Revenue i-1.5%4.3%
Net Income (Profit) i-38.55M1.68B
Profit Margin i-5.4%15.2%

Balance Sheet & Liquidity Metrics

MetricSUPN (2025)HLN (2025)
Cash & Equivalents i128.45M1.26B
Total Current Assets i644.18M4.55B
Total Current Assets % of Revenue i89.6%41.3%
Total Current Liabilities i338.17M4.93B
Total Current Liabilities % of Revenue i47.0%44.7%
Long-Term Debt i30.37M7.75B
Long-Term Debt % of Revenue i4.2%70.2%
Total Shareholders Equity i1.06B16.48B
Retained Earnings i517.88M27.85B
Retained Earnings % of Revenue i72.0%252.5%
Property, Plant & Equipment i01.00M

Cash Flow Statement Comparison

MetricSUPN (2025)HLN (2025)
Operating Cash Flow i67.28M2.19B
Operating Cash Flow % of Revenue i9.4%19.8%
Capital Expenditures i-1.34M-322.00M
Free Cash Flow i45.99M2.22B
FCF Margin i6.4%20.1%
Debt Repayment i0-1.35B
Common Stock Repurchase iN/A-654.00M

Short Interest & Institutional Ownership Analysis

MetricSUPNHLN
Shares Short i4.53M19.28M
Short Ratio i7.262.14
Short % of Float i11.09%0.43%
Shares Outstanding i57.46M8.91B
Float Shares i51.79M8.86B
% Held by Insiders i4.34%0.01%
% Held by Institutions i105.00%12.74%
% Held by Public i-9.34%87.25%

Dividend Analysis & Yield Comparison: Supernus Pharmaceuticals Inc. vs Haleon Plc - ADR

MetricSUPNHLN
Last 12-Month Dividend iN/A$0.17
Last 12-Month Dividend Yield iN/A1.63%
3-Year Avg Annual Dividend iN/A$0.11
3-Year Avg Dividend Yield iN/A0.91%
3-Year Total Dividends iN/A$0.34
Ex-Dividend DateN/AApr 25, 2025